Bishal Gyawali

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Bishal Gyawali
May 31, 2025, 09:56 | Blog
Amol Akhade Shares Virtual Attendance Tips for ASCO 2025
Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, posted on X: "My X…
May 28, 2025, 15:18 | Blog
Dinesh Raj Neupane Talked about Financial Toxicity of Cancer at the Public Health Conference
Dinesh Raj Neupane shared a post on LinkedIn: "FINANCIAL TOXICITY OF CANCER Yesterday, at the…
May 27, 2025, 13:51 | Blog
Pre-ASCO 2025 Event with The University of Illinois Cancer Center - Common Sense Oncology
Common Sense Oncology shared a post on LinkedIn: "Attending ASCO 2025? Join us in Chicago…
May 25, 2025, 10:12 | Blog
Bishal Gyawali: Register for the CSO Symposium
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on X: "Just 1 more week…
May 21, 2025, 17:41 | Opinion
Bishal Gyawali addressed G7 cancer drug approval claims about Canada with the Lancet Oncology Study
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on X about the article…
May 19, 2025, 10:58 | Blog
Bishal Gyawali: President Biden’s Diagnosis of Metastatic Prostate Cancer
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on X: "I am saddened to…
May 17, 2025, 17:38 | Science
Chiara Corti: Decoding Clinical Trials in Metastatic Breast Cancer - Practical Insights for Optimal Therapy Sequencing
Chiara Corti, Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: "NEW…
May 14, 2025, 16:30 | Blog
A Special CSO Webinar Featuring the Principal Investigators of the SONIA Trial
Common Sense Oncology shared on LinkedIn: "Join us for a special CSO webinar featuring the…
May 14, 2025, 08:15 | Insight
Bishal Gyawali: The validity of DFS as a surrogate endpoint for OS in pancreatic cancer trials
Bishal Gyawali, Associate Professor at Queen’s University, shared on LinkedIn: "Have you read our new…
May 13, 2025, 01:25 | Blog
Bishal Gyawali: Thank you to the WHO for the privilege of joining the EML Expert Panel Committee
Bishal Gyawali, Associate Professor at Queen’s University, shared on LinkedIn: "Thank you to the World…
May 10, 2025, 10:10 | Blog
Thaís Baccili Cury Megid Shares Meta-Analysis Supporting DFS as Surrogate for OS in Pancreatic Cancer
Thaís Baccili Cury Megid, Medical Oncologist at Vitalité Health Network, posted on LinkedIn: "I am…
May 9, 2025, 17:19 | Insight
Bishal Gyawali: I Hope Trial Sponsors and Trialists Will Find These Results Helpful and Meaningful
Bishal Gyawali, Associate Professor at Queen's University, shared on X about a recent paper shared…
May 5, 2025, 14:43 | Blog
Jasmine Kamboj: Join CoP Health Policy for latest updates and announcements
Jasmine Kamboj, Community Oncologist and Hematologist at Mayo Clinic and Podcast Editor and Host of…
Apr 30, 2025, 09:15 | Blog
Bishal Gyawali: Proud to serve as WHO Expert at 25th Meeting on Essential Medicines
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on LinkedIn: "I am proud…
Apr 27, 2025, 13:45 | Blog
Jasmine Kamboj: Webinar on Policy by Volunteer-Led Communities of Practice
Jasmine Kamboj, Community Oncologist and Hematologist at Mayo Clinic and Podcast Editor and Host of…
Apr 27, 2025, 12:20 | Blog
Common Sense Oncology will be at the ASCO 2025
Common Sense Oncology shared a post on X: "CSO will be at ASCO 2025! Join our…
Apr 24, 2025, 17:36 | Blog
Bishal Gyawali: WHO EML working group discussion on checkpoint inhibitors for solid cancers
Bishal Gyawali, Associate Professor at Queen's University, shared a post on LinkedIn: "I hope you…
Apr 21, 2025, 13:21 | Positive
Bishal Gyawali: I love teaching and consider it a huge honour
Bishal Gyawali, Associate Professor Queen's University, shared a post on LinkedIn: "I love teaching and…
Apr 20, 2025, 23:10 | Blog
Bishal Gyawali: A Positive Step Towards Addressing Regulatory Capture
Bishal Gyawali, Associate Professor at Queen’s University, shared a post by Chief Nerd, adding: "This is…
Apr 18, 2025, 01:25 | Blog
Bishal Gyawali: Teaching Is a Huge Honour – Thank You, GLPH 488 Class
Bishal Gyawali,  Associate Professor Queen’s University, shared a post on X: "I love teaching and…
Apr 7, 2025, 09:01 | Blog
Bishal Gyawali: Explore Two New Publications This Week!
Bishal Gyawali, Associate Professor at Queen’s University, posted on LinkedIn: "Looking for some good weekend…
Apr 6, 2025, 01:57 | Insight
Bishal Gyawali: Treatment Innovations in Pancreatic Cancer
Bishal Gyawali, Associate Professor at Queen’s University, posted on LinkedIn about recent article he and…
Apr 2, 2025, 12:33 | Blog
Bishal Gyawali: Congruence of cancer screening recommendations between the USPSTF and the top ten US cancer centers
Bishal Gyawali, Associate Professor at Queen’s University, posted on LinkedIn about recent article he and…
Apr 2, 2025, 10:29 | Science
Bishal Gyawali: Congruence of cancer screening recommendations between the USPSTF and the top ten US cancer centers
Bishal Gyawali, Associate Professor at Queen’s University, shared an article by Kristin Wright, et al.…
Mar 31, 2025, 11:21 | Blog
Courageous keynote lecture from Benjamin Besse
Rodrigo Lastra del Prado, Medical Oncologist of Thoracic Tumor Unit at University Hospital, Zaragoza, Spain,…
Mar 24, 2025, 17:27 | Science
A checklist for the discussants of clinical trials at major cancer meetings - Common Sense Oncology
Common Sense Oncology shared a post on X about a paper by Elizabeth Eisenhauer et…
Mar 22, 2025, 06:38 | Blog
Bishal Gyawali: Guidance for discussants of randomized cancer trials at major meetings
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X about recent…
Mar 18, 2025, 10:55 | Blog
Muharrem Coşkunpınar: A great talk from Bishal Gyawali at ASCO-AIOM CRC
Muharrem Coşkunpınar, Doctor of Medicine and Fellow at Ankara University, shared a post on X: "On…
Mar 12, 2025, 12:37 | Blog
Bishal Gyawali: Super excited about the ASCO-AIOM course in clinical research
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X: "Who else…
Mar 10, 2025, 08:32 | Blog
Bishal Gyawali: Surrogate endpoints in cancer drug trials
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X: "It’s Friday!…
Mar 2, 2025, 08:41 | Blog
Sharon’s inspiring story and the power of patient-driven research - Marathon of Hope Cancer Centres Network
Marathon of Hope Cancer Centres Network posted on LinkedIn: "Imagine forming Canada’s first breast cancer…
Mar 1, 2025, 16:11 | Blog
Nirmala Bhoo Pathy: Comprehensive analysis of cancer incidence and mortality across Southeast Asia
Nirmala Bhoo Pathy, Professor of Epidemiology in the Department of Social and Preventive Medicine at…
Feb 12, 2025, 08:12 | Blog
Enrique Soto: Proposals for the design, analysis, and reporting of Phase 3 RCTs in oncology
Enrique Soto, Geriatric oncologist and Editor-in-Chief of ecancer’s journal, shared an article he and colleagues…
Feb 11, 2025, 08:55 | Insight
Bishal Gyawali: This is why we need randomized controlled trials
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X about a…
Feb 6, 2025, 14:31 | Insight
Bishal Gyawali: A checklist to design and report cancer drug RCTs
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X about a…
Feb 6, 2025, 12:35 | Science
Bishal Gyawali: Celebrating World Cancer Day by pledging to improve the quality of our cancer RCTs
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared his recent article on X: "Let’s…
Feb 3, 2025, 08:17 | Blog
Bishal Gyawali: Our major publications from last 2 months
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, posted on X: "These last 2 months…
Feb 1, 2025, 08:37 | Blog
Bishal Gyawali about the Destiny Breast 06 trial at ESMO24
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on LinkedIn: "Destiny Breast…
Jan 29, 2025, 07:56 | Blog
Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
Laura Bukavina, Urologic Oncologist at Cleveland Clinic Urology, shared a post on X: "When control…
Jan 29, 2025, 07:37 | Blog
Bishal Gyawali: Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X: "Ever wondered…
Jan 27, 2025, 08:52 | Blog
Bishal Gyawali: Why Overall Survival Should Be The Oncology Trial Endpoint
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on LinkedIn: "Every time they…
Jan 25, 2025, 15:23 | Blog
Bishal Gyawali: Skills Lab - Clinical Trial Methods - Focus on the Control Arm
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on X: "New video just dropped…
Jan 22, 2025, 07:13 | Blog
Bishal Gyawali: Every time I talk about mentorship, I myself get inspired and energized
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on X: "Of the different…
Jan 18, 2025, 22:54 | Blog
Yakup Ergün: Patients' interests must always come first in clinical trials
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X by Bishal…
Jan 18, 2025, 08:44 | Science
Bishal Gyawali: Inferior Control Arms in Prostate Cancer Trials - The ARANOTE Trial
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, posted on X about recent paper by…
Jan 18, 2025, 07:39 | Blog
Bishal Gyawali: Pleasurd to do a keynote address at the 2025 CUCOH conference in Queen's University
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, shared a post on X: "For people…
Jan 17, 2025, 14:48 | Science
Bishal Gyawali: ESMO Global Consortium Study on the availability, affordability, and accessibility of cancers medicines
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, posted on X about recent paper by…
Jan 16, 2025, 12:30 | Dialogues
The Need for Common Sense Oncology - Global Cancer Movement
In the inaugural event of the Global Cancer Movement, initiated by OncoDaily, Dr. Bishal Gyawali…
Jan 14, 2025, 14:40 | Blog
Bishal Gyawali: Ever wondered how I read clinical trial reports?
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, posted on LinkedIn: "Ever wondered how I…
Jan 12, 2025, 20:04 | Blog
Bishal Gyawali: Financial Toxicity in Low- and Middle-Income Countries
Bishal Gyawali shared on LinkedIn: "We have just published in JCO Oncology Practice the most…
Jan 7, 2025, 17:24 | Science
Bishal Gyawali: One of the most important aspects of care is end of life care
Bishal Gyawali shared a post on X: "As medical oncologists, one of the most important aspects…
Jan 3, 2025, 09:20 | Blog
Bishal Gyawali: Looking back, 2024 was an excellent year
Bishal Gyawali, Associate Professor at Queen’s University, shared on LinkedIn: "Last day of 2024! Looking…
Dec 24, 2024, 18:11 | Blog
Bishal Gyawali: Are U.S. patients paying twice for cancer drugs?
Bishal Gyawali, Associate Professor at Queen’s University, shared on X: “Are U.S. patients paying twice…
Dec 21, 2024, 08:29 | Science
Bishal Gyawali: The case of cancer drug Xtandi
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, Canada, posted on LinkedIn about recent paper…
Dec 20, 2024, 10:43 | Blog
Bishal Gyawali: Honoured to lead patient-directed cancer therapy program
Bishal Gyawali, Associate Professor at Queen’s University, shared a post by Queen’s Health Sciences on…
Dec 8, 2024, 14:33 | Blog
Fellows of ASCO (FASCO) Recipients For This Quarter
The following members have earned the distinguished Fellows of ASCO (FASCO) recognition this quarter. This…
Dec 7, 2024, 10:28 | Blog
Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 1
The first day of our inaugural Global Cancer Movement, “Challenging the Status Quo in Colorectal…
Dec 7, 2024, 01:59 | Career
Bishal Gyawali: Pleased to represent Queen's Health Sciences into the FASCO directory
Bishal Gyawali, Associate Professor at Queen’s University, shared a post by ASCO on X, adding:…
Nov 30, 2024, 14:02 | Insight
First Results of the Dutch SONIA Trial on CDK4/6 Inhibitors
Evaluating the Impact of CDK4/6 Inhibitors in First- and Second-Line Endocrine Therapy for HR+, HER2-…
Nov 13, 2024, 16:25 | Insight
A clear picture of the ground reality
Bishal Gyawali, Associate Professor at Queen’s University, shared an article by S.S. Datta on LinkedIn,…
Nov 10, 2024, 17:10 | Opinion
Bishal Gyawali: Improving patient outcomes is all that matters
Bishal Gyawali, Associate Professor at Queen’s University, shared a tweet by Amol Akhade, Consultant Medical Oncologist…
Nov 8, 2024, 19:11 | Blog
Bishal Gyawali: What oncologists and cancer patients perceive as meaningful benefit or justified prices
Bishal Gyawali shared on LinkedIn: "One of the most important global oncology cancer policy studies our…
Oct 21, 2024, 19:24 | Blog
Bishal Gyawali: Proud to be an alumnus of the ASCO Leadership Development Program
Bishal Gyawali shared a post on X: ''Look what arrived in the mailbox today! Thank…
Oct 16, 2024, 14:38 | Blog
The challenges of implementing resource stratified guidelines in LMICs like Nepal, suggested by Bishal Gyawali
Bishal Gyawali shared a post on X: "I’ve never been much fan of resource stratified guidelines.…
Oct 15, 2024, 00:34 | Blog
Bishal Gyawali: 15 most FAQs about surrogate endpoints in oncology
Bishal Gyawali shared a post by Oncology News Central on X, adding: "My new piece in Oncology…
Oct 14, 2024, 17:49 | Blog
You don’t need the world’s permission to aim high and succeed - Bishal Gyawali about John Jumper's Nobel Prize
Bishal Gyawali, an Associate Professor at Queen’s University, Kingston, posted on X: "Wow, this is…
Oct 12, 2024, 10:21 | Blog
Bishal Gyawali Was Honored with ASCO Fellowship for Outstanding Contributions to Oncology
The Ontario Institute for Cancer Research (OICR) is a leading research institute dedicated to advancing…
Oct 9, 2024, 11:35 | Blog
Amol Akhade: The Tyranny of Non-Inferiority Trials
Amol Akhade posted the following on LinkedIn: “The Tyranny of Non-Inferiority Trials. Excellent view by…
Oct 4, 2024, 17:19 | Blog
Bishal Gyawali: Our CSO Symposium in Vall d’Hebron Hospital
Bishal Gyawali shared a post on X: "I had the pleasure of speaking with Oncoinfo during…
Oct 1, 2024, 17:35 | Insight
Frequently asked questions on surrogate endpoints in oncology via Bishal Gyawali et al.
Ash Paul, Medical Director of EoE Specialised Commissioning Group, shared a post on X about…
Sep 29, 2024, 17:04 | Blog
Bishal Gyawali: Patient perspectives on overtreatment, clinical trials, and quality of life
Bishal Gyawali reposted on X: "This is a brilliant and poignant piece highlighting patient perspectives…
Sep 26, 2024, 14:22 | Blog
Luis Castelo-Branco: Belzutifan vs everolimus for advanced kidney cancer
Luis Castelo-Branco shared a post on X: ''Belzutifan vs everolimus for advanced kidney cancer: NO…
Sep 25, 2024, 15:17 | Blog
Bishal Gyawali: My talk at the Common Sense Oncology symposium during ESMO24 is now available
Bishal Gyawali shared on X: "Recording from my talk at the Common Sense Oncology symposium…
Sep 21, 2024, 00:07 | Insight
Bishal Gyawali: What questions can you think of regarding surrogate endpoints in oncology
Bishal Gyawali shared a post on X about a recent paper by Abhenil Mittal et…
Sep 19, 2024, 12:01 | Insight
Bishal Gyawali: ‘Father of MCBS’ highlights how biases are being addressed in the MCBS tool
Bishal Gyawali shared a post on X: “First talk of the session: Nathan Cherny the…
Sep 19, 2024, 08:32 | Blog
Bishal Gyawali: Health expenditure inversely proportional to what actually leads to mortality reduction
Bishal Gyawali shared on X: What a great point from Dr. Rodrigo Lastra del Prado.…
Sep 18, 2024, 09:35 | Blog
Dario Trapani: Superstar moment at ESMO24
Dario Trapani shared a post on X: ''Superstar moment at ESMO24. Bishal Gyawali presenting on…
Sep 15, 2024, 15:12 | Blog
Enrique Soto: Time Toxicity among older adults with cancer
Bishal Gyawali shared an article by Enrique Soto on X: "Important data on time toxicity among…
Sep 14, 2024, 17:16 | Societies
Highlights of the CSO symposium from ESMO24
The Common Sense Oncology symposium, hosted by Drs. Bishal Gyawali, Winnette van der Graaf, Dario…
Sep 14, 2024, 17:15 | Societies
45 Posts not to miss from ESMO24 Day 1
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Sep 11, 2024, 18:27 | Blog
Bishal Gyawali: Time to apply for the Common Sense Oncology fellowship in cancer policy
Bishal Gyawali shared a post on X by Common Sense Oncology, adding: "Time to apply…
Aug 29, 2024, 17:23 | Blog
Common Sense Oncology at ESMO24
Common Sense Oncology posted on X: "Attending ESMO24? Join us on September 13th Friday from…
Aug 21, 2024, 19:41 | Blog
Bishal Gyawali: 2 most important tables you'll need for VTE prophylaxis and treatment with DOACs
Bishal Gyawali posted on X about recent paper by him as coauthor, titled "Assessing the…
Aug 15, 2024, 14:51 | Blog
Amol Akhade: Our editorial in BMJ Oncology focusing on Geriatric Oncology in LMICs
Amol Akhade, Consultant medical hemato oncologist at Suyog cancer clinics and Reliance Hospitals, shared his…
Aug 15, 2024, 04:34 | Blog
Bishal Gyawali: Describing the cancer burden in SAARC region
Bishal Gyawali posted on LinkedIn about recent paper by Urvish Jain et al., titled "Cancer…
Aug 15, 2024, 04:20 | Blog
Bishal Gyawali: 2 papers published on the same day in BMJ Oncology
Bishal Gyawali shared on X: "Personal Record: 2 papers published in the same journal on the…
Aug 14, 2024, 17:48 | Insight
Geriatric oncology in LMICs
Recently, an article titled "Geriatric oncology in LMICs: it is time to mature" was published…
Aug 12, 2024, 13:37 | Blog
Oncoinfluencers to Follow on Social Media: Dr. Bishal Gyawali
At OncoDaily, we are excited to feature Dr. Bishal Gyawali, a renowned medical oncologist, as…
Aug 8, 2024, 12:53 | Blog
How to interpret phase 3 cancer clinical trials hosted by Bishal Gyawal - Common Sense Oncology
Common Sense Oncology shared a post on X: ''Join us for a CSO lecture on…
Aug 4, 2024, 11:53 | Blog
Skills Lab: Interpreting Clinical Research with Bishal Gyawali is now live
Bishal Gyawali shared a post on X about his recent paper, commenting: “Big announcement! Skills…
Aug 3, 2024, 12:57 | Blog
Bishal Gyawali: Revolving door between the regulators and the industry
Bishal Gyawali shared a post on X: "Revolving door between the regulators and the industry,…
Jul 26, 2024, 08:55 | Blog
Michelle Li: The Common Sense Oncology movement is one to which we should all belong
Michelle Li, Breast cancer fellow at Peter Mac Cancer Centre, shared on X about an article…
Jul 26, 2024, 06:54 | Insight
Discussions around updated OS data from Aegean Trial
AEGEAN trial is a phase 3 trial that tested the combination of perioperative durvalumab, a…
Jul 24, 2024, 15:42 | Blog
Bishal Gyawali: Explaining cancer in simple terms isn’t easy
Bishal Gyawali shared a post on LinkedIn: "Explaining cancer in simple terms isn’t easy. This…
Jul 18, 2024, 09:04 | Blog
Bishal Gyawali: My thoughts on the NADINA trial
Bishal Gyawali shared a post on X: "My thoughts on the NADINA trial."  . Further…
Jul 18, 2024, 07:11 | Insight
Bishal Gyawali: Quality of Life reporting remains disappointing even for those trials that lead to drug approvals
Bishal Gyawali shared a post on X about a recent paper by Medhavi Gupta et…
Jul 5, 2024, 01:33 | Blog
Aruni Ghose: A MUST READ - penned down by Mona Hassan and Akash Maniam
Aruni Ghose shared a post by Akash Maniam, Medical Oncologist at Portsmouth Hospitals University NHS…
Jun 28, 2024, 11:54 | Career
Dr. Khaled Zaza appointed Head of Department of Oncology at Queen's University Faculty of Health Sciences
Bishal Gyawali shared on X:             . "What an amazing happy…
Jun 27, 2024, 12:11 | Insight
Patrick Forde: What is an acceptable rate of crossover?
Patrick Forde, Co-Director of the Division of Upper Aerodigestive Malignancies Sidney Kimmel Comprehensive Cancer Center at…
Jun 24, 2024, 02:11 | Blog
Bishal Gyawali: Very productive meeting of the MCBS working group
Bishal Gyawali shared on X:               . "We had a…
12
All: 179 Posts: 1 - 100
Special Coverage